Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 30;24(11):9507.
doi: 10.3390/ijms24119507.

Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Adrianna Radulska  1 , Iwona Pelikant-Małecka  1 , Kamila Jendernalik  1 , Iwona T Dobrucki  2   3   4 , Leszek Kalinowski  1   5
Affiliations
Review

Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Adrianna Radulska et al. Int J Mol Sci. .

Abstract

Skin diseases such as psoriasis (Ps) and psoriatic arthritis (PsA) are immune-mediated inflammatory diseases. Overlap of autoinflammatory and autoimmune conditions hinders diagnoses and identifying personalized patient treatments due to different psoriasis subtypes and the lack of verified biomarkers. Recently, proteomics and metabolomics have been intensively investigated in a broad range of skin diseases with the main purpose of identifying proteins and small molecules involved in the pathogenesis and development of the disease. This review discusses proteomics and metabolomics strategies and their utility in research and clinical practice in psoriasis and psoriasis arthritis. We summarize the studies, from in vivo models conducted on animals through academic research to clinical trials, and highlight their contribution to the discovery of biomarkers and targets for biological drugs.

Keywords: in vivo mouse models; metabolomics; proteomics; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Basic techniques used in proteomic/metabolomic analysis and their utility in psoriasis. (B) Catalogue of future candidate proteomic and metabolomic biomarkers differentiating psoriasis and psoriatic arthritis [100]. Black font represents biomarkers identified in both diseases and green/yellow fonts correspond, respectively, to Ps and PsA.
See this image and copyright information in PMC

References

    1. Yan D., Gudjonsson J.E., Le S., Maverakis E., Plazyo O., Ritchlin C., Scher J.U., Singh R., Ward N.L., Bell S., et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J. Investig. Dermatol. 2021;141:2112–2122.e3. doi: 10.1016/j.jid.2021.02.764. - DOI - PMC - PubMed
    1. Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed
    1. Borzęcki A., Koncewicz A., Raszewska-Famielec M., Dudra-Jastrzębska M. Epidemiology of Psoriasis in the Years 2008–2015 in Poland. Przegl. Dermatol. 2018;105:693–700. doi: 10.5114/dr.2018.80837. - DOI
    1. Purzycka-Bohdan D., Kisielnicka A., Zabłotna M., Nedoszytko B., Nowicki R.J., Reich A., Samotij D., Szczęch J., Krasowska D., Bartosińska J., et al. Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life. J. Clin. Med. 2022;11:1254. doi: 10.3390/jcm11051254. - DOI - PMC - PubMed
    1. Michalek I.M., Loring B., John S.M. A Systematic Review of Worldwide Epidemiology of Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:205–212. doi: 10.1111/jdv.13854. - DOI - PubMed